Scarica l'app Stockscreener
43.54
1.05%
-0.46
Dopo l'orario di chiusura:
43.61
0.07
+0.16%
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
When Will Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Become Profitable? - Moomoo
What Ionis Pharmaceuticals (IONS)'s Phase 3 Wins Mean For Shareholders - Simply Wall Street
Return on invested capital % of Ionis Pharmaceuticals, Inc. – HAN:ISI - TradingView
Ionis Pharmaceuticals, Inc. Revenue Breakdown – HAN:ISI - TradingView
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - Yahoo Finance
BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’ - Stocktwits
Ionis Pharmaceuticals Inc. (IONS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
CCORF Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $85 - Moomoo
Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide - Yahoo Finance
IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval - Stocktwits
Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis - Yahoo Finance
IONS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating on trial data - Investing.com
Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS) - The Globe and Mail
Oppenheimer reiterates Ionis stock rating on late-stage wins By Investing.com - Investing.com Canada
Ionis Pharmaceuticals, Inc. (IONS) Options ChainYahoo Finance - Yahoo! Finance Canada
Otsuka, Ionis notch phase III win in FUS-ALS - BioWorld News
IONIS Pharmaceuticals (NASDAQ: IONS) Announces Positive Interim Phase 3 Data for Sefaxersen in IgA Nephropathy - Kalkine Media
Ionis Pharmaceuticals and Roche Announce Positive Phase 3 Interim Results for Sefaxersen in IgA Nephropathy - Kalkine Media
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs - Zacks Investment Research
Roche, Ionis RNA drug scores in kidney disease study - BioPharma Dive
IONS Looks 5.2% Undervalued on GF Value™ Amid RNA Therapy Trial News - GuruFocus
Ionis Pharmaceuticals' Phase 3 kidney trial meets proteinuria endpoint - Mugglehead Investment Magazine
Otsuka, Ionis to Discuss Approval Path for FUS-ALS Drug With Regulators - GenomeWeb
Ionis Pharmaceuticals stock hits 52-week low at $44.20 By Investing.com - Investing.com India
Ionis Pharmaceuticals stock hits 52-week low at $44.20 - Investing.com
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease - AOL.com
BMO reiterates Ionis Pharmaceuticals stock rating on ALS drug data By Investing.com - Investing.com Canada
Roche, Ionis post trial win for kidney drug (IONS:NASDAQ) - Seeking Alpha
Form 8K IONIS PHARMACEUTICALS For: 23 September By Investing.com - Investing.com Nigeria
Canaccord reiterates Ionis stock rating on positive trial results By Investing.com - Investing.com Canada
Ionis reports positive Phase 3 interim results for sefaxersen in IgA nephropathy - TradingView
Otsuka and Ionis report positive data in Phase III FUSION trial of ulefnersen - Yahoo
Otsuka and Ionis report positive Phase III readout for ulefnersen - The Pharma Letter
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN) - BioSpace
Ionis, Roche report positive phase 3 data for kidney drug - Investing.com
Ionis, Roche report positive phase 3 data for kidney drug By Investing.com - Investing.com Australia
Ionis Pharmaceuticals, Inc. (IONS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ionis and Otsuka Report Positive Phase 3 Data for FUS-ALS Drug Ulefnersen - finance.biggo.com
IONS Looks 7.0% Undervalued on GF Value™ - GuruFocus
Ionis to Seek Expedited FDA Review for ALS Drug - Benzinga
IONS Looks 7.2% Undervalued on GF Value™ Amid Mixed Growth and P - GuruFocus
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - TradingView
Otsuka, Ionis’ experimental ALS drug meets main goal in late-stage study - 101 WIXX
JPMorgan cuts Ionis Pharmaceuticals stock price target on launch concerns By Investing.com - Investing.com UK
Ionis drug meets primary goal in rare ALS gene mutation trial - Investing.com Canada
Ionis drug meets primary goal in rare ALS gene mutation trial By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile - TradingView
Ionis Pharmaceuticals Price Target Cut to $70.00/Share From $76.00 by JP Morgan - moomoo.com
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS - Yahoo Finance
(IONS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
High Growth Tech Stocks To Watch In The US September 2026 - simplywall.st
Ionis Pharmaceuticals, Inc. (IONS): Investor Outlook On An 88.61% Potential Upside - DirectorsTalk Interviews
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - Yahoo Finance
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):